Becton Dickinson pays $175M for misleading investors about flawed IV pump system
By 
Adrianne Appel2024-12-18T18:08:00
Becton Dickinson (BD) medical device company will pay $175 million for “repeatedly” misleading investors about its Alaris infusion pump, a product the company knew was flawed and was sold without the required patient-safety approvals, the Securities and Exchange Commission (SEC) said.
Manufacturers are required to get approvals from the Food and Drug Administration (FDA) for complex medical devices like infusion pumps.
The FDA approval process involves submitting detailed data showing a device is safe and effective. BD, one of the largest device manufacturers in the world, with 70,000 employees, received 10 percent of its profits from sales of the pump.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
ArticleFormer ADM execs inflated operating profits, SEC alleges
Three former executives at Archer-Daniels-Midland intentionally misled investors by inflating the performance of the company’s Nutrition unit, the U.S. Securities and Exchange Commission has alleged.
-
News BriefInnovasis, execs settle false claims case for $12M
Medical device manufacturer Innovasis and two of its top executives agreed to pay a total of $12 million to settle allegations originally brought by a whistleblower that they paid kickbacks to physicians.
-
Blog
Becton, Dickinson & Co. promotes CECO to general counsel
Global medical technology firm Becton, Dickinson and Company announced the promotion of Chief Ethics and Compliance Officer Michelle Quinn to general counsel.
More from Regulatory Enforcement
-
ArticleEU investigation into Grok may expose problems with DSA rather than compliance failings
The European Commission has launched a formal investigation against Elon Musk’s X under the Digital Services Act over fears that its AI tool Grok may be producing and disseminating illegal material.
-
ArticleSFO head to step down as speculation grows over future of agency
Nick Ephgrave, director of the U.K.’s main anti-corruption enforcement agency, the Serious Fraud Office, will retire at the end of March—about halfway through his appointed five-year term. Experts say he leaves the agency in a lot better position than he joined it in September 2023.
-
News BriefFTC puts GM’s puts connected vehicle data practices under compliance spotlight
The U.S. Federal Trade Commission finalized its order against General Motors and its OnStar subsidiary over the improper usage of geolocation and driving behavior data of drivers.